Physician profile
Arnab Biswas
NPI 1134216930
$5,230.85
in general payments reported to CMS, 2019-2025
21 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $397 · 2021: $853 · 2022: $997 · 2023: $855 · 2024: $1,002 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.92 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,122.20 | 2019-2025 | Mavyret, Linzess, Rinvoq |
| Gilead Sciences, INC. | $782.77 | 2019-2025 | Epclusa |
| Pfizer INC. | $393.85 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299.02 | 2019-2024 | Entyvio |
| Madrigal Pharmaceuticals | $276.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.85 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $225.59 | 2019-2025 | Tremfya, Stelara |
| Medtronic, INC. | $206.68 | 2021-2022 | |
| Astellas Pharma US INC | $150.23 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $108.20 | 2019-2024 | Dificid |
| Genzyme Corporation | $71.99 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $64.38 | 2020-2024 | Clenpiq, Rebyota |
| Phathom Pharmaceuticals, INC. | $48.61 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $46.52 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $33.78 | 2023 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $31.22 | 2024 | Ibsrela |
| Redhill Biopharma INC. | $30.54 | 2021-2022 | |
| Lilly USA, LLC | $24.48 | 2024 | Omvoh |
| Celgene Corporation | $22.90 | 2021 | |
| Allergan, INC. | $22.83 | 2019 | |
| Apollo Endosurgery US INC | $10.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnab Biswas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.